• Profile
Close

Efficacy and safety of spore-forming probiotics in the treatment of functional dyspepsia: A pilot randomized, double-blind, placebo-controlled trial

The Lancet: Gastroenterology & Hepatology Aug 09, 2021

Wauters L, Slaets H, De Paepe K, et al. - Treatment with probiotics (Bacillus coagulants MY01 and Bacillus subtilis MY02, 2·5 × 10'9 colony-forming units per capsule) was identified as efficacious and safe in functional dyspepsia.

  • This is a single-center, randomized, double-blind, placebo-controlled pilot trial.

  • Higher proportion of clinical responders was recorded among patients assigned to receive probiotics (48%) vs placebo (20%).

  • Adult patients (≥ 18 years) with functional dyspepsia (as defined by Rome IV criteria, on proton-pump inhibitors or off proton-pump inhibitors) exhibit potentially beneficial immune and microbial changes.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay